5-FUOncology News Saladax Biomedical Welcomes New Guidelines from the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT) for 5-Fluorouracil Therapy
5-FU Saladax Biomedical, Inc. Announces the Presentation of the CESAR Study Results for Pharmacokinetically-Guided Dosing of 5-Fluorouracil in Colorectal Cancer at 2015 ASCO Meeting
